Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor LMF LaMiaFinanza - 08/01/2019 02:30:17 (updated 02/09/2019 11:51:13) To view full article click here